跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 39,715 条关于
“TRUST-II”
全部
39,715
临床试验
34,118
药物
289
机构
304
资讯
5,004
去年
Taletrectinib Shows Promise in ROS1-Positive NSCLC, Including TKI-Pretreated Patients
2年前
Taletrectinib Shows Durable Responses in Advanced ROS1-Positive NSCLC
昨天
FDA Approves Taletrectinib Label Update Showing 49.7-Month Median Duration of Response in ROS1+ NSCLC
去年
Taletrectinib Approved in China for ROS1-Positive NSCLC, Showing Promise in TKI-Pretreated and Naive Patients
去年
Nuvation Bio's Taletrectinib Gains FDA Priority Review and Expanded Access Program for ROS1+ NSCLC
前天
Taletrectinib Shows Consistent Efficacy Across ROS1+ NSCLC Subgroups Regardless of Prior Chemotherapy or Fusion Partner
2年前
Taletrectinib Demonstrates Efficacy in ROS1-Positive NSCLC, Regardless of Prior TKI Exposure
2年前
Taletrectinib Shows Promise in ROS1-Positive NSCLC: Nuvation Bio Announces Positive Phase 2 Data
昨天
FDA Approves Updated IBTROZI Label With Nearly 50-Month Duration of Response in TKI-Naive ROS1+ NSCLC
去年
Innovent's Taletrectinib (DOVBLERON®) Receives Expanded Approval in China for ROS1-Positive NSCLC
第 1 页,共 501 页
上一页
下一页